HAVCR2 and neoplasm: The interaction between TIM3 and its ligand, Galectin-9 (LGALS9), triggers T-cell dysfunction characterized by impaired proliferative capacity and cytokine secretion deficiency, ultimately fostering tumor-associated immunosuppression and immune escape mechanisms [38, 39].